Incyte Roars Ahead with a Flurry of Milestones By Mark TerryApril 11, 2023 Wilmington, Del.-based Incyte had an enormously busy March and April, with several big announcements and reports. Steven [….]
Incyte Roars Ahead with a Flurry of Milestones
Weekly Quick Hits (Greater Philly) – Week of April 3, 2023
Weekly Quick Hits (Greater Philly) – Week of April 3, 2023 By Mark Terry, Alex Keown, and Sarah EllinwoodApril 7, 2023 Funding, Awards and Collaborations Jefferson U to Expand Jefferson [….]
Weekly Quick Hits (Greater Philly) – Week of March 27, 2023
Weekly Quick Hits (Greater Philly) – Week of March 27, 2023 By Mark Terry, Alex Keown, and Sarah EllinwoodMarch 31, 2023 A special thank you to everyone who came out [….]
Incyte Q4 2022: Total Revenues Hit $3.4 Billion, with New Drug Opzelura Growing Fast
In the conference call with investors, company CEO Hervé Hoppenot noted that “2022 was another successful year in which we delivered strong performance and made significant progress across our oncology and dermatology pipeline.”
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
Incyte (Nasdaq:INCY) today announced new data from two of its LIMBER (Leadership In MPNs and GVHD BEyond Ruxolitinib) trials evaluating monotherapy and combination strategies using ruxolitinib (Jakafi®) with parsaclisib, its investigational phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, and INCB00928 (zilurgisertib), its activin receptor-like kinase (ALK2) inhibitor, in patients with myelofibrosis (MF). These Phase 2 and Phase 1/2 trials (Abstract #236 and Abstract #1714, respectively) were presented at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-13, 2022, in New Orleans and virtually1,2.
5 Questions With Michelle Kinder, Ph.D., Director of Translational Sciences at Incyte
I was attracted to Incyte for its immuno-oncology pipeline. When I first joined Incyte as a Scientific Director, Immuno-Oncology in U.S. Medical Affairs, I had the opportunity to support the growing pipeline, explore novel biology and enable our therapeutics into clinical practice.
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
Incyte (NASDAQ:INCY) today announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. Its lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023.
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency’s (EMA) has issued a positive opinion that recommends granting marketing authorization for capmatinib (Tabrecta®) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymalepithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.